TABLE 6

Treatment-emergent AEs (preferred terms) occurring in >5% of patients in any group (SS)a

ParameterValue
CadazolidVancomycin (125 mg QID) (n = 22)
250 mg BID (n = 20)500 mg BID (n = 22)1,000 mg BID (n = 20)
No. of patients with at least one TEAE6 (30.0)5 (22.7)6 (30.0)10 (45.5)
Total no. of TEAEs16152244
Patients with at least one TEAE by preferred term [n (%)]
    Headache2 (10.0)2 (9.1)1 (5.0)3 (13.6)
    Dizziness1 (5.0)1 (4.5)1 (5.0)2 (9.1)
    Confusional state2 (10.0)
    Dyspepsia1 (5.0)1 (4.5)2 (9.1)
    Pruritus2 (9.1)1 (4.5)
    Pain in extremity2 (9.1)
    Rash2 (9.1)
  • a The SS included all randomized patients who received ≥1 dose of the study drug.